SAN DIEGO, CA -- (Marketwire) -- 04/08/10 -- Medistem Inc. (PINKSHEETS: MEDS) was corresponding author on a recently published peer-reviewed medical paper describing what is believed to be the first demonstration of a significant increase in circulating stem cells in healthy volunteers induced by a non-drug product.
The study is available at http://www.translational-medicine.com/content/pdf/1479-5876-8-34.pdf
Following up on a previously published pilot study, the current investigation assessed blood levels of endothelial progenitor cells and hematopoietic stem cells in 18 patients who ingested the nutraceutical product Stem-Kine. Assessment of stem cell levels was performed by flow cytometry and functional assays.
"Everyone in the regenerative medicine arena is looking for ways of increasing efficacy of existing stem cell therapies. Medistem's interest in the Stem-Kine product revolves around the vision of using a commercially available food supplement as an adjuvant to the company's proprietary endometrial regenerative cell approach," said Thomas Ichim, CEO of Medistem.
Medistem's endometrial regenerative cells are currently being developed as a treatment for an advanced form of peripheral artery disease termed critical limb ischemia, which causes approximately 150,000 amputations per year in the US. Medistem is collaborating with several universities and companies at identifying ways to increase regenerative activity of stem cells.
"It is becoming more and more apparent that recipient health factors contribute to efficacy of stem cell therapy. The demonstration that nutritional supplementation can increase circulation of endogenous stem cells opens new avenues for optimizing adult stem cell therapies," concluded Thomas Ichim.
About Medistem Inc.
Medistem Inc. is a biotechnology company founded to develop and commercialize technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company's lead product, the endometrial regenerative cell (ERC), is a "universal donor" stem cell being developed for critical limb ischemia.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.